通策醫療(600763.SH):控股股東質押230萬股
格隆匯6月10日丨通策醫療(600763.SH)公佈,公司2021年6月10日接到控股股東杭州寶羣實業集團有限公司(“寶羣實業”)股票質押交易通知,此次質押股份數為230萬股,佔寶羣實業所持有公司股份數的2.13%,佔公司總股份數的0.72%。
此次質押後,寶羣實業質押股份總數為4400萬股,佔寶羣實業所持有公司股份數的40.65%,佔公司總股份數的13.72%;寶羣實業的一致行動人呂建明持股總數109.4萬股,佔總股本的0.34%,並無質押;寶羣實業已質押股份數佔寶羣實業及其一致行動人所持有公司股份數的40.25%,佔公司總股份數的13.72%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.